Physician profile
Scott M Eshowsky
NPI 1285622373
$3,537.48
in general payments reported to CMS, 2019-2025
37 companies · $191 in 2025
The $191 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $465 · 2021: $1,268 · 2022: $1,027 · 2023: $93.83 · 2024: $140 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $405 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $405.49 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $575.98 | 2019-2023 | Wegovy |
| Abbvie INC. | $485.16 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.94 | 2021-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $253.12 | 2019-2022 | |
| Amgen INC. | $186.26 | 2019-2024 | Evenity, Prolia |
| Sanofi-Aventis U.S. LLC | $165.19 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $158.84 | 2020-2024 | Gardasil 9, Gardasil, Vaxelis |
| Amarin Pharma, INC. | $142.32 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $132.60 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $125.22 | 2020-2025 | Farxiga, Airsupra |
| Dexcom, INC. | $114.28 | 2021-2022 | |
| Glaxosmithkline, LLC. | $108.54 | 2019-2025 | Shingrix |
| Janssen Pharmaceuticals, INC | $66.50 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.89 | 2022-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $58.44 | 2022-2025 | Rexulti |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $57.82 | 2024-2025 | Azstarys |
| Eisai INC. | $54.99 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $51.03 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $36.65 | 2022 | |
| Esperion Therapeutics, INC. | $35.46 | 2021 | |
| Paratek Pharmaceuticals, INC. | $33.97 | 2021-2022 | |
| Lilly USA, LLC | $32.33 | 2019-2025 | Jardiance |
| Insulet Corporation | $28.19 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.31 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $26.24 | 2020 | |
| Shire North American Group INC | $17.95 | 2019 | |
| Sanofi Pasteur INC. | $17.83 | 2022 | |
| Janssen Biotech, INC. | $17.20 | 2019 | |
| Seqirus USA INC | $17.17 | 2024 | Fluad, Flucelvax |
| Astellas Pharma US INC | $16.52 | 2023 | Veozah |
| Inspire Medical Systems, INC. | $15.57 | 2025 | Inspire |
| Pfizer INC. | $14.95 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.80 | 2021 | |
| Ibsa Pharma INC. | $12.72 | 2021 | |
| Celgene Corporation | $11.99 | 2019 | |
| Dermira, INC. | $11.47 | 2020 | |
| Zyla Life Sciences, INC. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Eshowsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.